Sweden
· Delayed Price · Currency is SEK Alligator Bioscience AB Statistics
Total Valuation
Alligator Bioscience AB has a market cap or net worth of SEK 399.49 million. The enterprise value is 361.65 million.
| Market Cap | 399.49M |
| Enterprise Value | 361.65M |
Important Dates
The next estimated earnings date is Friday, February 7, 2025.
| Earnings Date | Feb 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Alligator Bioscience AB has 758.04 million shares outstanding. The number of shares has increased by 95.35% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 758.04M |
| Shares Change (YoY) | +95.35% |
| Shares Change (QoQ) | +2.22% |
| Owned by Insiders (%) | 0.03% |
| Owned by Institutions (%) | 6.98% |
| Float | 477.33M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 13.15 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.46 |
| EV / Sales | 13.02 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.35
| Current Ratio | 0.35 |
| Quick Ratio | 0.32 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -22.98 |
Financial Efficiency
Return on equity (ROE) is -8,427.12% and return on invested capital (ROIC) is -874.37%.
| Return on Equity (ROE) | -8,427.12% |
| Return on Assets (ROA) | -108.72% |
| Return on Capital (ROIC) | -874.37% |
| Revenue Per Employee | 590,936 |
| Profits Per Employee | -5.28M |
| Employee Count | 58 |
| Asset Turnover | 0.20 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +22.24% in the last 52 weeks. The beta is 1.35, so Alligator Bioscience AB's price volatility has been higher than the market average.
| Beta (5Y) | 1.35 |
| 52-Week Price Change | +22.24% |
| 50-Day Moving Average | 1.03 |
| 200-Day Moving Average | 1.10 |
| Relative Strength Index (RSI) | 25.20 |
| Average Volume (20 Days) | 2,201,058 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Alligator Bioscience AB had revenue of SEK 27.77 million and -248.31 million in losses. Loss per share was -0.36.
| Revenue | 27.77M |
| Gross Profit | -154.34M |
| Operating Income | -239.96M |
| Pretax Income | -248.31M |
| Net Income | -248.31M |
| EBITDA | -239.72M |
| EBIT | -239.96M |
| Loss Per Share | -0.36 |
Balance Sheet
The company has 47.80 million in cash and 9.96 million in debt, giving a net cash position of 37.84 million or 0.05 per share.
| Cash & Cash Equivalents | 47.80M |
| Total Debt | 9.96M |
| Net Cash | 37.84M |
| Net Cash Per Share | 0.05 |
| Equity (Book Value) | -76.00M |
| Book Value Per Share | -0.10 |
| Working Capital | -108.26M |
Cash Flow
| Operating Cash Flow | -233.19M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -863.96% |
| Pretax Margin | -894.02% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Alligator Bioscience AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -95.35% |
| Shareholder Yield | -95.35% |
| Earnings Yield | -67.99% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Alligator Bioscience AB has an Altman Z-Score of -25.92. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -25.92 |
| Piotroski F-Score | n/a |